356 related articles for article (PubMed ID: 31987674)
1. The BRAF p.V600E mutation is a common event in ameloblastomas but is absent in odontogenic keratocysts.
Zhang R; Yang Q; Qu J; Hong Y; Liu P; Li T
Oral Surg Oral Med Oral Pathol Oral Radiol; 2020 Mar; 129(3):229-235. PubMed ID: 31987674
[TBL] [Abstract][Full Text] [Related]
2. Frequent oncogenic BRAF V600E mutation in odontogenic keratocyst.
Cha YH; Cho ES; Kang HE; Ko J; Nam W; Kim HJ; Kim NH; Kim HS; Cha IH; Yook JI
Oral Oncol; 2017 Nov; 74():62-67. PubMed ID: 29103753
[TBL] [Abstract][Full Text] [Related]
3. The molecular basis of odontogenic cysts and tumours.
Gomes IP; Bastos VC; Guimarães LM; Gomes CC
J Oral Pathol Med; 2023 Apr; 52(4):351-356. PubMed ID: 36629457
[TBL] [Abstract][Full Text] [Related]
4. BRAF V600E and previously unidentified KRAS G12C mutations in odontogenic tumors may affect MAPK activation differently depending on tumor type.
Oh KY; Kim JH; Cho SD; Yoon HJ; Lee JI; Hong SD
Genes Chromosomes Cancer; 2022 Aug; 61(8):481-490. PubMed ID: 35353428
[TBL] [Abstract][Full Text] [Related]
5. Utility of BRAF V600E immunohistochemistry in the diagnosis of mandibular ameloblastomas.
Ji YD; Johnson DN; Faquin WC; Peacock ZS
Int J Oral Maxillofac Surg; 2024 Feb; 53(2):122-126. PubMed ID: 37344275
[TBL] [Abstract][Full Text] [Related]
6. High frequency of BRAF V600E mutation in Iranian population ameloblastomas.
Derakhshan S; Aminishakib P; Karimi A; Saffar H; Abdollahi A; Mohammadpour H; Kharazi Fard MJ; Memarha A
Med Oral Patol Oral Cir Bucal; 2020 Jul; 25(4):e502-e507. PubMed ID: 32388526
[TBL] [Abstract][Full Text] [Related]
7. [BRAF V600E expression in ameloblastomas, ameloblastic carcinomas and cysts].
Pei J; Zhang L; Jia YX; Chen WH
Shanghai Kou Qiang Yi Xue; 2023 Dec; 32(6):630-634. PubMed ID: 38494972
[TBL] [Abstract][Full Text] [Related]
8. Genetic Study of
Kokubun K; Yamamoto K; Akashi Y; Chujo T; Nakajima K; Matsuzaka K
Int J Surg Pathol; 2022 Jun; 30(4):378-384. PubMed ID: 34994576
[No Abstract] [Full Text] [Related]
9. Detection and evaluation of the presence of the BRAF V600E mutation in ameloblastomas in an Indian population.
Goes CF; Spadigam A; Dhupar A; Carvalho KM; Cota J; Syed S
Indian J Pathol Microbiol; 2023; 66(2):246-251. PubMed ID: 37077063
[TBL] [Abstract][Full Text] [Related]
10. Odontogenic keratocyst and ameloblastoma: radiographic evaluation.
Kitisubkanchana J; Reduwan NH; Poomsawat S; Pornprasertsuk-Damrongsri S; Wongchuensoontorn C
Oral Radiol; 2021 Jan; 37(1):55-65. PubMed ID: 32030659
[TBL] [Abstract][Full Text] [Related]
11. Assessment of BRAFV600E and SMOF412E mutations in epithelial odontogenic tumours.
Diniz MG; Gomes CC; Guimarães BV; Castro WH; Lacerda JC; Cardoso SV; de Faria PR; Dias FL; Eisenberg AL; Loyola AM; Gomez RS
Tumour Biol; 2015 Jul; 36(7):5649-53. PubMed ID: 25854168
[TBL] [Abstract][Full Text] [Related]
12. BRAF p.V600E status in epithelial areas of ameloblastoma with different histological aspects: Implications to the clinical practice.
Sant'Ana MSP; Dos Santos Costa SF; da Silva MP; Martins-Chaves RR; Pereira TDSF; de Oliveira EM; Martínez Pedraza R; de Castro WH; Gomes CC; Gomez RS; Fonseca FP
J Oral Pathol Med; 2021 May; 50(5):478-484. PubMed ID: 33377543
[TBL] [Abstract][Full Text] [Related]
13. The importance of BRAF-V600E mutation to ameloblastoma metabolism.
Duarte-Andrade FF; Silva AMB; Vitório JG; Canuto GAB; Costa SFS; Diniz MG; Fernandes AP; de Toledo JS; André LC; Gomes CC; Gomez RS; Fonseca FP
J Oral Pathol Med; 2019 Apr; 48(4):307-314. PubMed ID: 30739334
[TBL] [Abstract][Full Text] [Related]
14. Activating FGFR2-RAS-BRAF mutations in ameloblastoma.
Brown NA; Rolland D; McHugh JB; Weigelin HC; Zhao L; Lim MS; Elenitoba-Johnson KS; Betz BL
Clin Cancer Res; 2014 Nov; 20(21):5517-26. PubMed ID: 24993163
[TBL] [Abstract][Full Text] [Related]
15. Association of MDM2 Overexpression in Ameloblastomas with
Tosios KI; Kalogirou EM; Koutlas IG
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396916
[TBL] [Abstract][Full Text] [Related]
16. Discrepancy between immunohistochemistry and sequencing for BRAF V600E in odontogenic tumours: Comparative analysis of two VE1 antibodies.
Oh KY; Cho SD; Yoon HJ; Lee JI; Hong SD
J Oral Pathol Med; 2021 Jan; 50(1):85-91. PubMed ID: 32939809
[TBL] [Abstract][Full Text] [Related]
17. Current concepts in ameloblastoma-targeted therapies in B-raf proto-oncogene serine/threonine kinase V600E mutation: Systematic review.
González-González R; López-Verdín S; Lavalle-Carrasco J; Molina-Frechero N; Isiordia-Espinoza M; Carreón-Burciaga RG; Bologna-Molina R
World J Clin Oncol; 2020 Jan; 11(1):31-42. PubMed ID: 31976308
[TBL] [Abstract][Full Text] [Related]
18. The Mutational Profile of Unicystic Ameloblastoma.
Heikinheimo K; Huhtala JM; Thiel A; Kurppa KJ; Heikinheimo H; Kovac M; Kragelund C; Warfvinge G; Dawson H; Elenius K; Ristimäki A; Baumhoer D; Morgan PR
J Dent Res; 2019 Jan; 98(1):54-60. PubMed ID: 30216733
[TBL] [Abstract][Full Text] [Related]
19. Adenoid ameloblastoma with dentinoid is molecularly different from ameloblastomas and adenomatoid odontogenic tumors.
Coura BP; Dos Santos JN; Fonseca FP; Bernardes VF; de Aquino SN; Jorge Júnior J; Vargas PA; Romañach MJ; de Andrade BAB; Gomez RS; Gomes CC
J Oral Pathol Med; 2021 Nov; 50(10):1067-1071. PubMed ID: 34549835
[TBL] [Abstract][Full Text] [Related]
20. The diagnostic utility of BRAF VE1 mutation-specific immunohistochemistry in ameloblastoma.
Mendez LD; Wolsefer NS; Asa SL; Wasman J; Yoest JM; Stojanov IJ
Mod Pathol; 2022 Nov; 35(11):1570-1577. PubMed ID: 35676332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]